BRIEF: MedBot reports strong year-to-date sales as commercialization accelerates

Shanghai MicroPort MedBot (Group) Co. Ltd. (2252.HK) said on Wednesday that cumulative orders for its core products, including laparoscopic, orthopedic, and vascular intervention surgical robots, surpassed 170 units as of this week.

Orders for its flagship product, the Toumai laparoscopic surgical robot, exceeded 100 units alone, with nearly 80 delivered worldwide, making it the dominant domestic player for such products. The company emphasized that its commercialization process has entered an accelerated phase.

Toumai is the first domestically developed laparoscopic robotic system to enter the global market. Overseas orders topped 60 units across 40 countries and regions spanning Asia, Europe, Africa, Oceania and South America, the company said.

Shares of MedBot opened down 1% at HK$32.86 on Thursday. The stock is up 250% since the beginning of the year.

By Lau Chi Hang

To subscribe to Bamboo Works weekly free newsletter, click here